(Q34107414)

31 July 2017

1 reference

title

Pleiotropic effects of statins. (English)

1 reference

31 July 2017

1 reference

Farmer JA

1

1 reference

31 July 2017

1 May 2000

1 reference

Current Atherosclerosis Reports

31 July 2017

1 reference

31 July 2017

2

1 reference

31 July 2017

208-217

1 reference

31 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-000-0022-3

31 July 2017

0 references

cites work

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0022-3

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0022-3

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0022-3

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0022-3

Levels of soluble cell adhesion molecules in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0022-3

Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-000-0022-3

The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro

21 January 2018

1 reference

12 December 2020

Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability.

1 reference

12 December 2020

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

12 December 2020

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors

1 reference

12 December 2020

A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA

1 reference

12 December 2020

Gender differences in blood thrombogenicity in hyperlipidemic patients and response to pravastatin

1 reference

12 December 2020

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

12 December 2020

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

1 reference

12 December 2020

Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction.

1 reference

12 December 2020

Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes

1 reference

12 December 2020

Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients

1 reference

12 December 2020

Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin

1 reference

12 December 2020

Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin

1 reference

12 December 2020

Platelet Deposition on Eroded Vessel Walls at a Stenotic Shear Rate Is Inhibited by Lipid-Lowering Treatment With Atorvastatin

1 reference

12 December 2020

Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia

1 reference

12 December 2020

Statins and fibrinogen

1 reference

12 December 2020

Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets

1 reference

12 December 2020

Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells

1 reference

12 December 2020

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

1 reference

12 December 2020

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

1 reference

12 December 2020

Comparison of plasma tissue factor levels in unstable and stable angina pectoris.

1 reference

12 December 2020

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

1 reference

12 December 2020

Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin

1 reference

12 December 2020

Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus

1 reference

12 December 2020

Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line

1 reference

12 December 2020

Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

1 reference

12 December 2020

HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis

1 reference

12 December 2020

Tissue factor in atherosclerosis

1 reference

12 December 2020

Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia.

1 reference

12 December 2020

Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy

1 reference

12 December 2020

Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes

1 reference

12 December 2020

Cholesterol lowering and endothelial function

1 reference

12 December 2020

The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits

1 reference

12 December 2020

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

12 December 2020

Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach

1 reference

12 December 2020

In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.

1 reference

12 December 2020

Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines

1 reference

12 December 2020

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

12 December 2020

Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain

1 reference

12 December 2020

Carcinogenicity of lipid-lowering drugs

1 reference

12 December 2020

Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats

1 reference

12 December 2020

Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin

1 reference

12 December 2020

10.1007/S11883-000-0022-3

Identifiers

DOI

1 reference

PubMed ID

11122746

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11122746